Andreas trained as Clinical Pharmacologist and has additional degrees in Pharmaceutical Medicine and Business Management (EMBA, IMD Lausanne).
He joined F. Hoffmann-La Roche after a Clinical Research Fellowship at the University Hospital of Leiden, the Netherlands in 1992. At Roche, he was initially responsible for clinical “proof of concept” studies and later took on the leadership for several early and late stage clinical development programs and successful filings. In 2007, he became Global Head of Clinical Research & Exploratory Development. Under his leadership Discovery Research and Clinical Research became better connected, and translational medicine became a key driver to implement the Personalized Healthcare strategy of Roche.
After Roche’s acquisition of Genentech, he was appointed in 2010 as Senior Vice President and Head of Roche pRED Development. In 2012, he took on, additionally, the role of Head of the Cardiovascular & Metabolism Disease (CVM) R&D business unit. In 2014, Roche decided to exit the CVM franchise for strategic reasons, and Andreas decided to leave Roche.
He subsequently founded a Life Sciences Consulting company and advised management and boards of biotech companies on R&D strategy, drug development, and organizational management. Between 2016 and 2017, Andreas acted as interim Head of Development of Polyphor Ltd., a Swiss biotech company, and revised the strategy of their lead clinical antibiotic program. He led Polyphor with a small team successfully through the regulatory meetings with FDA and EMA, which subsequently allowed the company to raise a next large financing round.
In 2016, Andreas joined in his principal role as General Partner BioMed Partners, a leading Swiss and European Venture Capital company. In July 2017, he associated his Pharma consultancy with Certara Ltd. as a Senior Executive Advisor.